New‐onset lung sarcoidosis, an adverse event by COVID‐19 or a sign of convalescence; a case report
Key Clinical Message Sarcoidosis is a systemic inflammatory disease able to affect any organ within the body. Sarcoidosis may be the body's secondary response to COVID‐19 infection and a sign of rehabilitation. Early response to the treatments reinforces this hypothesis. The majority of sarcoid...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-05-01
|
| Series: | Clinical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ccr3.7339 |
| _version_ | 1827941448296693760 |
|---|---|
| author | Somayeh Sadeghi Shadi Reisizadeh Mobarakeh Mahnaz Momenzadeh Amir Aria Mitra Heidarpour Somayeh Haji Ahmadi Zohreh Naderi |
| author_facet | Somayeh Sadeghi Shadi Reisizadeh Mobarakeh Mahnaz Momenzadeh Amir Aria Mitra Heidarpour Somayeh Haji Ahmadi Zohreh Naderi |
| author_sort | Somayeh Sadeghi |
| collection | DOAJ |
| description | Key Clinical Message Sarcoidosis is a systemic inflammatory disease able to affect any organ within the body. Sarcoidosis may be the body's secondary response to COVID‐19 infection and a sign of rehabilitation. Early response to the treatments reinforces this hypothesis. The majority of sarcoidosis patients require immunosuppressive therapies, including corticosteroids. Abstract Most studies so far have focused on the management of COVID‐19 in patients suffering from sarcoidosis. Nevertheless, the current report aims to present a COVID‐19‐induced sarcoidosis case. Sarcoidosis is a systemic inflammatory disease with granulomas. Still, its etiology is unknown. It often affects the lungs and lymph nodes. A previously healthy 47‐year‐old female was referred with the following chief complaints: atypical chest pain, dry cough, and dyspnea on exertion within a month after COVID‐19 infection. Accordingly, a chest computed tomography revealed multiple conglomerated lymphadenopathies in the thoracic inlet, mediastinum, and hila. A core‐needle biopsy from the nodes revealed non‐necrotizing granulomatous inflammation, sarcoidal type. The sarcoidosis diagnosis was proposed and confirmed by a negative purified protein derivative (PPD) test. Accordingly, prednisolone was prescribed. All symptoms were relieved. A control lung HRCT was taken 6 months later, showing the lesions had disappeared. In conclusion, sarcoidosis may be the body's secondary response to COVID‐19 infection and a sign of disease convalescence. |
| first_indexed | 2024-03-13T09:38:21Z |
| format | Article |
| id | doaj.art-6382ffd3f46f4d7bac2fc182c2a8f236 |
| institution | Directory Open Access Journal |
| issn | 2050-0904 |
| language | English |
| last_indexed | 2024-03-13T09:38:21Z |
| publishDate | 2023-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical Case Reports |
| spelling | doaj.art-6382ffd3f46f4d7bac2fc182c2a8f2362023-05-25T05:58:39ZengWileyClinical Case Reports2050-09042023-05-01115n/an/a10.1002/ccr3.7339New‐onset lung sarcoidosis, an adverse event by COVID‐19 or a sign of convalescence; a case reportSomayeh Sadeghi0Shadi Reisizadeh Mobarakeh1Mahnaz Momenzadeh2Amir Aria3Mitra Heidarpour4Somayeh Haji Ahmadi5Zohreh Naderi6Acquired Immunodeficiency Research Center, Al‐Zahra Hospital Isfahan University of Medical Sciences Isfahan IranDepartment of Internal Medicine, Alzahra Hospital Isfahan University of Medical Sciences Isfahan IranDepartment of Clinical Pharmacy and Pharmacy Practice Isfahan University of Medical Sciences Isfahan IranDepartment of Internal Medicine, Alzahra Hospital Isfahan University of Medical Sciences Isfahan IranDepartment of Pathology Isfahan University of Medical Sciences Isfahan IranDepartment of Radiology, School of Medicine Isfahan University of Medical Sciences Isfahan IranAcquired Immunodeficiency Research Center, Al‐Zahra Hospital Isfahan University of Medical Sciences Isfahan IranKey Clinical Message Sarcoidosis is a systemic inflammatory disease able to affect any organ within the body. Sarcoidosis may be the body's secondary response to COVID‐19 infection and a sign of rehabilitation. Early response to the treatments reinforces this hypothesis. The majority of sarcoidosis patients require immunosuppressive therapies, including corticosteroids. Abstract Most studies so far have focused on the management of COVID‐19 in patients suffering from sarcoidosis. Nevertheless, the current report aims to present a COVID‐19‐induced sarcoidosis case. Sarcoidosis is a systemic inflammatory disease with granulomas. Still, its etiology is unknown. It often affects the lungs and lymph nodes. A previously healthy 47‐year‐old female was referred with the following chief complaints: atypical chest pain, dry cough, and dyspnea on exertion within a month after COVID‐19 infection. Accordingly, a chest computed tomography revealed multiple conglomerated lymphadenopathies in the thoracic inlet, mediastinum, and hila. A core‐needle biopsy from the nodes revealed non‐necrotizing granulomatous inflammation, sarcoidal type. The sarcoidosis diagnosis was proposed and confirmed by a negative purified protein derivative (PPD) test. Accordingly, prednisolone was prescribed. All symptoms were relieved. A control lung HRCT was taken 6 months later, showing the lesions had disappeared. In conclusion, sarcoidosis may be the body's secondary response to COVID‐19 infection and a sign of disease convalescence.https://doi.org/10.1002/ccr3.7339COVID‐19dyspneagranulomalymphadenopathysarcoidosis |
| spellingShingle | Somayeh Sadeghi Shadi Reisizadeh Mobarakeh Mahnaz Momenzadeh Amir Aria Mitra Heidarpour Somayeh Haji Ahmadi Zohreh Naderi New‐onset lung sarcoidosis, an adverse event by COVID‐19 or a sign of convalescence; a case report Clinical Case Reports COVID‐19 dyspnea granuloma lymphadenopathy sarcoidosis |
| title | New‐onset lung sarcoidosis, an adverse event by COVID‐19 or a sign of convalescence; a case report |
| title_full | New‐onset lung sarcoidosis, an adverse event by COVID‐19 or a sign of convalescence; a case report |
| title_fullStr | New‐onset lung sarcoidosis, an adverse event by COVID‐19 or a sign of convalescence; a case report |
| title_full_unstemmed | New‐onset lung sarcoidosis, an adverse event by COVID‐19 or a sign of convalescence; a case report |
| title_short | New‐onset lung sarcoidosis, an adverse event by COVID‐19 or a sign of convalescence; a case report |
| title_sort | new onset lung sarcoidosis an adverse event by covid 19 or a sign of convalescence a case report |
| topic | COVID‐19 dyspnea granuloma lymphadenopathy sarcoidosis |
| url | https://doi.org/10.1002/ccr3.7339 |
| work_keys_str_mv | AT somayehsadeghi newonsetlungsarcoidosisanadverseeventbycovid19orasignofconvalescenceacasereport AT shadireisizadehmobarakeh newonsetlungsarcoidosisanadverseeventbycovid19orasignofconvalescenceacasereport AT mahnazmomenzadeh newonsetlungsarcoidosisanadverseeventbycovid19orasignofconvalescenceacasereport AT amiraria newonsetlungsarcoidosisanadverseeventbycovid19orasignofconvalescenceacasereport AT mitraheidarpour newonsetlungsarcoidosisanadverseeventbycovid19orasignofconvalescenceacasereport AT somayehhajiahmadi newonsetlungsarcoidosisanadverseeventbycovid19orasignofconvalescenceacasereport AT zohrehnaderi newonsetlungsarcoidosisanadverseeventbycovid19orasignofconvalescenceacasereport |